Cohance Lifesciences Shares Drop Nearly 6% Amid Block Deal Buzz

Mumbai, September 18, 2025 – Shares of Cohance Lifesciences Limited (NSE: COHANCE) slipped sharply in Thursday’s early trade, tumbling 5.93% to ₹909 apiece at 09:16 IST, after reports of a major promoter stake sale through block deals.

Since going public in March 2020, Cohance Lifesciences Limited has operated within the pharmaceuticals industry and is included in the NIFTY Smallcap 250 index. The company’s stocks have a face value of ₹1 each, and the company remains an important player in the specialty pharma space.

Stock Movement and Trading Activity

At 11 am, the stock was trading at ₹913.60, down ₹52.75 or 5.46% from the previous close of ₹966.35. The share price opened at ₹906 and fell to an intraday low of ₹906 – the intraday high was ₹921.90, with volumes traded at over 358.46 lakh shares till now and a transaction value greater than ₹3,248.99 crore by mid-morning trading. Even with this fall, demand appeared to be strong with buy orders at 59.7 lakh shares versus sell orders at 4.83 lakh shares.

Promoter Stake Sale Buzz

Market sources believe that the decline was partially driven by the announcement from promoter holding Jusmiral Holdings that it might sell approximately 5.1% of its stake in Cohance via block trades, with the deal size being approximately ₹1,756 crore and a floor price of ₹900 per share, which is a discount of 6.9% to the previous day’s close.

Then again, it was confirmed in reports that Jusmiral Holdings had sold 3.39 crore shares, or 8.9% equity, for ₹3,073 crore. Other sources said a 210-day lock-up period would apply in the event of any additional sales. IIFL Capital was the book-running lead manager on the deal.

Company and Market Context

At the end of June 2025, Jusmiral Holdings had a 33.34% interest in Cohance Lifesciences. Cohance Lifesciences, based in Hyderabad, provides comprehensive pharmaceutical and biotech services, spanning from early-stage research to large-scale manufacturing. In May 2025, it was rebranded as Cohance Lifesciences from Suven Pharmaceuticals.

The stock continues to show high volatility near the 52-week low of ₹856.30 with an adjusted P/E ratio of 147.96. It has gained 7.6% in the past month and is still down 9.7% for six months.

Outlook

Cohance Lifesciences is currently facing near-term pressure due to heavy selling of promoter stakes; however, the strong interest in block sale deals indicates ongoing investor interest in the company’s name. Long-term growth for the company may rely on the demand for the CDMO space, while volatility in stock value may not be resolved until the overhang of promoter interests is removed.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations